Biomarin Pharmaceutical Inc

NASDAQ: BMRN
$68.96
-$0.55 (-0.8%)
Closing Price on October 7, 2024

BMRN Stock Chart and Intraday Price

BMRN Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 105 DIGITAL DRIVE, NOVATO, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 16,441.23M USD
Shares Outstanding 188,676,000
BioMarin Pharmaceutical Inc. specializes in creating innovative treatments for individuals facing serious and life-threatening rare diseases. With a portfolio that includes enzyme replacement therapies like Vimizim for mucopolysaccharidosis and Naglazyme for MPS VI, BioMarin stands out in the pharmaceutical field. The company also offers Kuvan for phenylketonuria, Palynziq to manage blood phenylalanine levels, Brineura for Batten disease, Voxzogo for achondroplasia, and Aldurazyme for issues related to the enzyme alpha-L-iduronidase. Additionally, BioMarin is developing Roctavian for severe hemophilia A, demonstrating its commitment to addressing unmet medical needs worldwide. Founded in 1996, BioMarin is headquartered in San Rafael, California.

BMRN Articles

Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Coherent, Coinbase Global, Conagra Brands, Coty, Hertz Global, Netflix, Plug Power, Rivian Automotive, Transocean,...
Wednesday's top analyst upgrades and downgrades included Amazon.com, BioMarin Pharmaceutical, Constellation Brands, Dominion Energy, Lucid, Nike, Southern Company, Tesla, Valero Energy, Walgreens...
Wednesday's top analyst upgrades and downgrades included Alphabet, Danaher, Emerson Electric, Foot Locker, GoDaddy, Harley-Davidson, Meta Platforms, New York Community Bancorp, Nvidia, Prologis, Rio...
Friday's top analyst upgrades and downgrades included Adobe, Citigroup, FedEx, Foot Locker, Hewlett Packard Enterprise, Intel, Medical Properties Trust, Nike, Qualcomm, Skyworks Solutions, Takeda...
Wednesday's top analyst upgrades and downgrades included BioMarin Pharmaceutical, BlackRock, CF Industries, Constellation Energy, DocuSign, DraftKings, Mosaic, Norfolk Southern, Nvidia, RingCentral,...
These five top Goldman Sachs Conviction List stock picks have the largest upside to the firm's target prices. Growth investors concerned about market and economic uncertainty may want to have them in...
Wednesday's top analyst upgrades and downgrades included APA, Delta Air Lines, Generac, Lululemon Athletica, Microchip Technology, Paccar, Philip Morris International, Pinduoduo, Shopify,...
Wednesday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Eli Lilly, Home Depot, Medtronic, Palantir Technologies, Snowflake, Take-Two Interactive Software, Viatris and...
Monday’s additional top analyst upgrades and downgrades were on Advanced Micro Devices, Amgen, BioMarin Pharmaceutical, Caterpillar, Gilead Sciences, Hanesbrands, Honeywell International, Keurig Dr...
Friday’s top analyst upgrades and downgrades included Danaher, Exact Sciences, First Majestic Silver, First Solar, Illumina, KB Home, NetApp, Nvidia, Salesforce, Snowflake, Splunk and TechnipFMC.
These five stock picks from the Goldman Sachs Conviction List offer ideas for aggressive investors with longer time horizons and a higher risk tolerance to consider now. Two blue-chip sector leaders...
Tuesday's top analyst upgrades and downgrades included Atlassian, Autodesk, BioMarin Pharmaceutical, Darden Restaurants, DraftKings, eBay, Fortinet, LyondellBasell Industries, Riot Blockchain and WEC...
Monday's additional top analyst upgrades and downgrades included BioMarin Pharmaceutical, Micron Technology, Quanta Services, Sangamo Therapeutics, Silvergate Capital, T. Rowe Price and Zendesk.
Thursday's top analyst upgrades and downgrades included Analog Devices, Aptiv, CF Industries, Ford, Mosaic, Park Hotels & Resorts, Patterson-UTI Energy, Pinterest, Plug Power, Salesforce, Snap,...
These five Goldman Sachs Conviction List stock picks are ideas that aggressive investors with longer time horizons and a higher risk tolerance may want to consider, given the host of woes that...